

Nanexa reports preliminary key financial information for the period January-September 2023

As communicated in a press release on September 21, 2023, the Board of Directors of Nanexa AB decided, as a result of the announced rights issue, to change the date of the interim report for the period January-September 2023 to November 20, 2023. With this press release, preliminary financial key information for the current period is reported.

Preliminary (unaudited) key financial information for the reporting period July 1 - September 30, 2023

- Turnover amounted to: TSEK 6,683 (1,531)
- Operating profit (EBIT) amounted to: TSEK -6,488 (-11,927)
- Profit after tax amounted to: TSEK -6,694 (-12,045)
- Earnings per share amounted to: SEK -0.11 (-0.24)
- Cash flow for the period amounted to: TSEK -17,790 (-21,297)
- Cash and cash equivalents at end of period: TSEK 20,569 (45,608)

Preliminary (unaudited) key financial information for the reporting period January 1 - September 30, 2023

- Turnover amounted to: TSEK 22,511 (2,040)
- Operating profit (EBIT) amounted to: TSEK -25,258 (-40,112)
- Profit after tax amounted to: TSEK -25,247 (-40,639)
- Earnings per share amounted to: SEK -0.42 (-0.80)
- Cash flow for the period amounted to: TSEK -60,613 (-60,052)
- Cash and cash equivalents at end of period: TSEK 20,569 (45,608)

Figures in brackets refer to the corresponding period in the previous year.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

[Nanexa reports preliminary key financial information for the period January-September 2023](#)